company background image
0R2B logo

Danaher LSE:0R2B Stock Report

Last Price

US$241.62

Market Cap

US$175.0b

7D

-3.5%

1Y

25.1%

Updated

31 Oct, 2024

Data

Company Financials +

0R2B Stock Overview

Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.

0R2B fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis

0R2B passed our risk checks.

Danaher Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Danaher
Historical stock prices
Current Share PriceUS$241.62
52 Week HighUS$283.88
52 Week LowUS$191.32
Beta0.86
11 Month Change-11.87%
3 Month Change-12.01%
1 Year Change25.11%
33 Year Change-20.49%
5 Year Change79.26%
Change since IPO218.15%

Recent News & Updates

Recent updates

Shareholder Returns

0R2BGB Life SciencesGB Market
7D-3.5%0.2%-1.1%
1Y25.1%-19.9%10.2%

Return vs Industry: 0R2B exceeded the UK Life Sciences industry which returned -19.9% over the past year.

Return vs Market: 0R2B exceeded the UK Market which returned 10.2% over the past year.

Price Volatility

Is 0R2B's price volatile compared to industry and market?
0R2B volatility
0R2B Average Weekly Movement2.9%
Life Sciences Industry Average Movement4.3%
Market Average Movement4.8%
10% most volatile stocks in GB Market9.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0R2B has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0R2B's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196962,000Rainer Blairwww.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.

Danaher Corporation Fundamentals Summary

How do Danaher's earnings and revenue compare to its market cap?
0R2B fundamental statistics
Market capUS$175.02b
Earnings (TTM)US$3.93b
Revenue (TTM)US$23.74b

44.5x

P/E Ratio

7.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0R2B income statement (TTM)
RevenueUS$23.74b
Cost of RevenueUS$9.53b
Gross ProfitUS$14.22b
Other ExpensesUS$10.28b
EarningsUS$3.93b

Last Reported Earnings

Sep 27, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.45
Gross Margin59.87%
Net Profit Margin16.57%
Debt/Equity Ratio34.2%

How did 0R2B perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

20%

Payout Ratio